market perform
reason report
bottom line upgrad op rais
estim consensu pt increas see
upsid margin expect stabil rather
compress model consensu run rate annual
upsid non-acquir treatment growth de novo come on-
stream in-network op contract flat
yoy consensu margin view driven posit
stimul agent esa patient care cost improv importantli
leverag pois off-set pressur wage inflat
suppli rais ebitda less nci estim
mm consensu mm rais
ebitda less nci estim mm mm line
consensu guidanc look achiev view low
double-digit ebitda growth stori remain intact underli growth
end-stag renal diseas esrd non-acquir treatment growth
build-out de novo clinic acquisit differenti jv model
nephrologist cfo yoy tailwind
legal cost subsid fund combin capital-expenditure de
novo build-out acquir treatment growth flexibl de-lever
polici perspect oh ballot behind ca appear
headlin rather fundament risk new pt
contempl ev/ebitda
rais ebitda less nci estim mm
consensu mm driven revenu growth de
novo ramp improv flat margin vs bp
contract consensu view offer path return
normal low double-digit ebitda less nci growth de novo
ramp posit medicar base rate updat along increas adopt
mircera releas volum commit aranesp
mp increas volum in-network potenti corpor
initi around labor product could add upsid estim
rais ebitda less nci estim mm
mm revenu ebitda less nci ep beat
volum guid ramp stabl mix non-acquir treatment volum
growth yoy guid ramp expect
year due time de novo open divestitur
guidanc rang exhibit
ev ebitda multipl
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
net revenu mm
pleas refer page import disclosur price chart analyst certif
settlement rear view potenti volum upsid
beyond settlement brought member
in-network aug month headwind reimburs
guidanc contempl volum upsid
agreement cover member across commerci manag
medicaid volum upsid potenti offset lower
solid medicar rate updat partial off-set
rate pressur propos solid increas end-
stage renal diseas esrd freestand facil rate well
final rate propos rate exhibit
margin expect normal esa
transit aranesp mircera modest benefit
expect becom appar calcimimet
posit impact ebitda ex-calcimimet patient cost per
treatment trend yoy exhibit
chang ebitda guidanc mm
lower mm quarter reflect network
guidanc contempl potenti upsid sensipar
current gener market exhibit
low double-digit ebitda growth stori remain intact
underli growth end-stag renal diseas esrd non-acquir
treatment growth build-out de novo clinic acquisit
differenti jv model nephrologist exhibit
cffo yoy settlement elimin legal
expens lead acceler capit invest
leverag reduct capit deploy focus larg build-out
de novo clinic mainten debt paydown leverag ratio
cffo yoy compani expect open
de novo line last year exhibit
headlin risk ballot initi ca remain
oh measur ballot minim exposur ca
five clinic monitor ca ballot initi believ
could restrict access dialysi treatment ca medic
associ join fight initi ballot measur
link would limit dialysi clinic revenu averag
cost dialysi treatment state plu healthcar improv
cost revenu cap refund patient insur
upgrad op rais pt pt
contempl ev/ebitda ebitda less nci
estim mm risk valuat network
contract seek go network futur unfavor polici
chang dialysi execut challeng adopt mircera
upgrad op rais estim consensu pt increas
see upsid margin expect stabil rather compress
model consensu run rate annual upsid non-acquir treatment growth
de novo come on-stream in-network contract flat yoy
consensu margin view driven posit medicar rate updat calcimimet
rate upsid mircera erythropoietin stimul agent esa patient care cost improv
importantli leverag pois off-set pressur wage inflat suppli
rais ebitda less nci estim mm consensu mm
rais ebitda less nci estim mm mm line
consensu guidanc look achiev view low double-digit ebitda growth
stori remain intact underli growth end-stag renal diseas esrd non-acquir
treatment growth build-out de novo clinic acquisit differenti jv model
cfo yoy tailwind legal cost subsid fund
combin capital-expenditure de novo build-out acquir treatment growth flexibl
de-lever polici perspect oh ballot behind ca appear headlin
rather fundament risk new pt contempl
rais ebitda less nci estim mm consensu
mm driven revenu growth de novo ramp improv flat
margin vs bp contract consensu view offer path return
normal low double-digit ebitda less nci growth de novo ramp posit medicar
base rate updat along increas adopt mircera releas volum commit
aranesp mp increas volum in-network potenti corpor
initi around labor product could add upsid estim
rais ebitda less nci estim mm mm revenu
ebitda less nci ep beat volum guid ramp stabl mix non-acquir
treatment volum growth yoy guid ramp expect year
due time de novo open divestitur guidanc rang
driver ebitda le nci report ebitda less assum treatment growth tailwind de novosmedicar rate base per treatment yoymircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate normal normal investmentstreat cost wage pressur yoy increas suppli cost increas contract mm headwind leerink ebitda less tailwindsheadwindsleerinkconsensusleerinkconsensusleerinkconsensusleerinkconsensusrevenu growth ebitda less nci ebitda less nci chang american renal associ hold inc
increas ebitda less nci estim mm
revenu ebitda ep consensu
driver ebitda le nci report ebitda less treatment revenu per treat growth volum volum ramp de novosmircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate continu one year outsid bundletreat cost wage pressur yoycommerci mix headwind mix stabil contract mm headwind networkg initi lobbi leerink ebitda less headwindstailwindsreport vs leerinkreport vs consensusqoqyoynet revenu ebitda less nci less nci bpsadj net incom dilut ep reportedvarianceara leerink consensu estim american renal associ hold inc
settlement rear view potenti volum upsid beyond
settlement brought member in-network aug month headwind
reimburs guidanc contempl volum upsid agreement cover
member across commerci manag medicaid volum upsid
potenti offset lower reimburs
solid medicar rate updat partial off-set rate pressur
propos solid increas end-stag renal diseas esrd freestand facil rate
well final rate propos rate
margin expect normal esa transit aranesp
mircera modest benefit expect becom appar
calcimimet posit impact ebitda ex-calcimimet patient cost per
treatment trend yoy
one thing highlight expens side signific progress make respect
adopt esa altern mircera june physician chosen convert mircera
primari esa nearli half clinic base strong physician interest long-act
esa expect clinic convert mircera year-end
joseph carlucci chairman ceo co-found
second half expect save mircera increas although
benefit off-set higher de novo start-up cost due open schedul
hospit ipp rate updat net increas propos final propos final propos final propos final propos final propos american renal associ hold inc
continu maintain effici cost structur establish result oper
initi patient care cost increas primarili result introduct calcimimet
underli patient cost trend rang remain consist expect
joseph carlucci chairman ceo co-found
expect calcimimet slight posit cost plu transit medicar
calcimimet expect dynam due time addit coverag non-medicar payer
introduct gener version sensipar increas physician adopt iv drug parsabiv
jason boucher cfo pend chief account offic vice-president financ treasur
transit continu manag well clinic oper mention first quarter
confer call patient therapi still consum oral calcimimet suppli earli part
prescript fill latter part result dynam well
broader payer coverag seen increas number patient receiv calcimimet
dialysi clinic oppos prescript drug plan
way would frame somewher dialysi patient receiv calcimimet
think consist experi seen realli three driver increas
full quarter patient receiv drug clinic set oppos part benefit
seen increas parsabiv also seen broader coverag non-medicar payer specif
reimburs medicar publish allow reimburs think look sort averag dose
would excess treatment medicar patient
guidanc tdapa
chang ebitda guidanc mm lower mm
quarter reflect in-network guidanc contempl potenti upsid
sensipar current gener market
low double-digit ebitda growth stori remain intact underli growth end-
stage renal diseas esrd non-acquir treatment growth build-out de novo
clinic acquisit differenti jv model nephrologist
consensu ebitda less nci base guidanc american renal associ hold inc
 dialysi popul grown compound-annual-growth-rate sinc
base current incid preval rate
estim esrd popul grow
end decad
similarli dialysi popul also expect
grow
dialysi popul ku esrd popul ku dialysi popul project american renal associ hold inc
clinic jv model offer growth still larg untap less
avail nephrologist base lead market share shift larg
dialysi organ apart high physician satisfact also continu
observ industry-lead patient satisfact suggest recent in-cent
hemodialysi consum assess healthcar provid system cahp
compound-annual-growth-rate
adj ebitda less nci growth
cffo yoy settlement elimin legal expens lead
acceler capit invest leverag reduct capit deploy focus
larg build-out de novo clinic mainten debt paydown leverag ratio
cffo yoy compani expect open de novo line last
net leverag came
estim de novo annual
headlin risk ballot initi ca remain oh measur ballot
minim exposur ca five clinic monitor ca ballot initi
believ could restrict access dialysi treatment ca medic associ join
fight initi ballot measur link would limit dialysi clinic revenu
averag cost dialysi treatment state plu healthcar improv
cost revenu cap refund patient insur compani
upgrad op rais pt pt contempl ev/ebitda
ebitda less nci estim mm risk valuat out-of-
network contract seek go in-network futur unfavor polici chang dialysi
execut challeng adopt mircera calcimimet
trade consensu ev/ebitda
pt contempl ev ebitda multipl revis ebitda less nci
estim mm
pt contempl ev/ebitda ebitda less nci estim
mm
downsid risk valuat includ
substanti reduct govern reimburs
lower margin shift patient privat insur provid medicar
govern program advers consequ new on-going litig
out-of-network contract seek go in-network
futur unfavor polici chang dialysi
execut challeng adopt mircera calcimimet
pt contempl ev/ebitda ebitda line recent multipl
competitor take-out privat equiti rang
downsid risk valuat includ
continu shift ambulatori could impact patient volum
pressur birthrat could impact children servic volum
continu anesthesia mix shift medicar could impact margin
medicaid payment may face cut state sponsor face budget pressur
potenti cut medicar physician fee schedul
revenu could advers affect net loss contract
incom statement mm except patient servic oper administr ebitda growth ebitda nci margin net incom incom tax less tax net incom attribut growth margin net outstand earn per growth growth american renal associ hold inc
